Dow Down0.17% Nasdaq Down0.28%

iBio, Inc. (IBIO)

0.61 0.03(5.09%) Sep 30, 4:00PM EDT
ProfileGet Profile for:
iBio, Inc.
9 Innovation Way
Suite 100
Newark, DE 19711
United States - Map
Phone: 302-355-0650

Index Membership:N/A
Full Time Employees:9

Business Summary 

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the company’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on iBio, Inc.

Key Executives 
Mr. Robert B. Kay , 74
Exec. Chairman and Chief Exec. Officer
Mr. Robert L. Erwin , 60
Mr. Terence E. Ryan Ph.D., 59
Chief Scientific Officer
Mr. Mark Giannone , 58
Chief Financial Officer
Mr. Douglas Hicks ,
VP of Bus. Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders